Phathom Pharmaceuticals Income Statement (2018-2026) | PHAT

Income Statement Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
0.68M1.91M7.32M16.35M29.66M28.52M39.50M49.50M57.58M58.30M74.27M
Cost of Revenue (Quarter)
0.17M0.43M1.38M2.36M3.81M3.72M5.04M6.19M7.65M12.00M15.10M
Gross Profit (Quarter)
0.52M1.49M5.95M14.00M25.85M24.80M34.47M43.31M49.94M46.30M59.18M
Operating items
Research & Development (Quarter)
16.61M13.55M17.66M18.82M19.02M15.95M11.48M12.76M12.26M13.39M9.43M7.38M8.69M8.58M9.18M9.08M7.03M7.49M7.77M7.81M
Selling, General & Administrative (Quarter)
16.53M19.49M20.25M26.55M23.51M30.70M18.60M18.94M23.40M57.00M62.01M75.87M76.10M76.68M94.47M85.31M51.56M48.37M54.01M55.33M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
33.14M33.04M37.91M45.36M42.53M46.64M30.08M31.70M35.66M70.39M71.44M83.25M84.79M85.27M103.66M94.39M58.59M55.86M61.78M63.14M
Operating Income (Quarter)
-33.14M-33.04M-37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M-5.93M-15.48M-3.96M
EBIT (Quarter)
-33.14M-33.04M-37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M-5.93M-15.48M-3.96M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M0.01M0.11M0.73M1.29M1.46M0.35M2.72M3.35M4.31M3.62M3.71M3.51M2.64M1.79M1.41M1.20M1.74M1.51M
Other Non Operating Income (Quarter)
-2.05M-0.02M-0.01M-0.00M-0.01M-0.09M0.02M0.00M-0.20M-0.01M-0.04M-0.01M-0.01M0.05M-0.02M-0.15M-0.01M-0.01M-0.83M-0.02M
Non Operating Income (Quarter)
-3.52M-2.79M-2.76M-5.56M-8.56M-8.40M-7.74M-9.26M-7.58M-9.70M-12.90M-14.15M-14.78M-15.03M-15.45M-15.89M-14.70M-15.22M-14.89M-13.62M
Net income details
EBT (Quarter)
-63.72M-35.81M-40.70M-50.92M-51.08M-67.72M-37.83M-46.29M-43.05M-65.06M-82.81M-91.44M-118.69M-74.50M-94.29M-83.42M-55.21M-10.15M-47.97M-28.00M
Profit After Tax (Quarter)
-36.66M-35.83M-40.66M-50.92M-51.09M-55.05M-37.81M-40.97M-43.24M-79.57M-82.85M-91.45M-85.58M-74.45M-94.32M-75.81M-29.97M-21.15M-30.37M-17.58M
Income from Continuing Operations (Quarter)
-63.72M-35.81M-40.70M-50.92M-51.08M-67.72M-37.83M-46.29M-43.05M-65.06M-82.81M-91.44M-118.69M-74.50M-94.29M-83.42M-55.21M-10.15M-47.97M-28.00M
Consolidated Net Income (Quarter)
-63.72M-35.81M-40.70M-50.92M-51.08M-67.72M-37.83M-46.29M-43.05M-65.06M-82.81M-91.44M-118.69M-74.50M-94.29M-83.42M-55.21M-10.15M-47.97M-28.00M
Income towards Parent Company (Quarter)
-63.72M-35.81M-40.70M-50.92M-51.08M-67.72M-37.83M-46.29M-43.05M-65.06M-82.81M-91.44M-118.69M-74.50M-94.29M-83.42M-55.21M-10.15M-47.97M-28.00M
Net Income towards Common Stockholders (Quarter)
-63.72M-35.81M-40.70M-50.92M-51.08M-67.72M-37.83M-46.29M-43.05M-65.06M-82.81M-91.44M-118.69M-74.50M-94.29M-83.42M-55.21M-10.15M-47.97M-28.00M
Additional items
EPS (Basic) (Quarter)
-1.71-0.97-1.07-1.33-1.32-1.73-0.89-0.95-0.76-1.27-1.42-1.56-1.84-1.18-1.31-1.15-0.75-0.14-0.58-0.33
EPS (Diluted) (Quarter)
-1.71-0.97-1.07-1.33-1.32-1.73-0.89-0.95-0.76-1.27-1.42-1.56-1.84-1.18-1.31-1.15-0.75-0.14-0.58-0.33
Shares Outstanding (Quarter)
37.30M37.00M38.04M38.27M38.82M39.12M42.35M48.50M56.78M51.29M58.37M58.56M64.63M63.18M71.97M72.47M73.40M72.92M82.05M83.75M
Shares Outstanding (Diluted) (Quarter)
37.30M37.00M38.04M38.27M38.82M39.12M42.35M48.50M56.78M51.29M58.37M58.56M64.63M63.18M71.97M72.47M73.40M72.92M82.05M83.75M
Shares Outstanding (Entity) (Quarter)
31.41M31.66M39.07M39.07M41.62M41.72M43.60M56.64M56.81M57.97M58.52M58.60M68.32M68.52M69.64M70.10M71.04M71.42M79.44M80.90M
EBITDA (Quarter)
-33.14M-33.04M-37.91M-45.36M-42.53M-46.64M-30.08M-31.70M-35.66M-69.88M-69.95M-77.30M-70.80M-59.42M-78.86M-59.92M-15.27M-5.93M-15.48M-3.96M
Interest Expenses (Quarter)
30.59M2.77M2.80M5.67M9.28M22.37M9.22M14.94M10.11M-1.47M17.17M17.76M51.60M18.59M18.07M25.28M41.35M5.43M34.23M25.54M